Rage (Receptor For Advanced Glycation End Products) Signaling Pathway In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
The Receptor for Advanced Glycation End Products (RAGE) is a pattern recognition receptor that binds diverse ligands including advanced glycation end products (AGEs), high mobility group box 1 (HMGB1), S100/calgranulin proteins, amyloid-beta (Aβ) fibrils, and DNA/histones. RAGE activation triggers pro-inflammatory, pro-oxidant, and pro-apoptotic signaling cascades that contribute to chronic neuroinflammation and neuronal dysfunction in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other neurodegenerative disorders. RAGE represents a promising therapeutic target, with several inhibitors and modulators in development.
RAGE is a multi-ligand pattern recognition receptor belonging to the immunoglobulin superfamily:
- Extracellular domain: V-type Ig-like domain (ligand binding) + two C-type Ig-like domains
- Transmembrane domain: Single pass membrane protein
- Intracellular domain: Cytoplasmic tail (required for signal transduction)
¶ Ligand Binding
flowchart TD
subgraph Ligands
A[AGEs]
B[HMGB1]
C[S100 Proteins]
D[Aβ Fibrils]
E[DNA/Histones]
end
subgraph RAGE Signaling
F[RAGE Receptor]
G[NF-κB Pathway]
H[MAPK Pathway]
I[Oxidative Stress]
J[Inflammasome]
end
A --> F
B --> F
C --> F
D --> F
E --> F
F --> G
F --> H
F --> I
F --> J
G --> K[Pro-inflammatory<br>Cytokines]
H --> L[Cell Proliferation<br>Survival]
I --> M[ROS Production]
J --> N[IL-1β, IL-18<br>Release]
K --> O[Chronic<br>Neuroinflammation]
L --> O
M --> O
N --> O
| Pathway |
Key Molecules |
Cellular Effects |
| NF-κB |
IKK, IκB, p65/p50 |
Pro-inflammatory gene expression |
| MAPK |
ERK1/2, JNK, p38 |
Cell proliferation, stress response |
| ROS production |
NADPH oxidase, mitochondria |
Oxidative stress |
| NLRP3 inflammasome |
ASC, pro-caspase-1 |
IL-1β, IL-18 maturation |
- Produced by alternative splicing or proteolytic cleavage
- Acts as a decoy receptor, sequestering ligands
- sRAGE levels correlate with disease status in some studies
RAGE-Aβ interaction is a critical pathogenic mechanism in AD:
- Synaptic localization: RAGE is expressed at synapses and co-localizes with Aβ
- Synaptic dysfunction: RAGE-Aβ signaling disrupts synaptic plasticity and memory
- Receptor for Aβ transport: RAGE mediates Aβ binding to neurons and glia
- Amplification loop: Aβ upregulates RAGE expression, creating a feed-forward cycle
- RAGE activation on microglia induces pro-inflammatory cytokine production
- NF-κB activation leads to TNF-α, IL-1β, IL-6 release
- Chronic neuroinflammation contributes to disease progression
- RAGE in hippocampus mediates Aβ-induced memory deficits
- RAGE inhibitors reverse memory impairment in animal models
- Genetic variants in RAGE may modify AD risk
RAGE contributes to dopaminergic neuron loss in PD:
- Oxidative stress: RAGE increases ROS production in dopaminergic neurons
- Mitochondrial dysfunction: RAGE signaling impairs mitochondrial function
- Neuroinflammation: RAGE activates microglia in substantia nigra
- RAGE can bind α-synuclein aggregates
- This may contribute to propagation of pathology
- RAGE expression is increased in PD brains
- RAGE is upregulated in ALS motor neurons and glia
- HMGB1-RAGE signaling contributes to excitotoxicity
- RAGE knockout mice show reduced motor neuron loss in some models
| Compound |
Mechanism |
Development Status |
| FPS-ZM1 |
RAGE Ig-like domain blocker |
Preclinical |
| Azeliragon (TTP488) |
RAGE antagonist |
Phase 2/3 AD |
| RAGE-i |
Small molecule inhibitor |
Preclinical |
| Anti-RAGE antibodies |
Neutralize RAGE ligands |
Preclinical |
- Broad ligand specificity: Multiple pathogenic ligands
- Expression patterns: RAGE has both beneficial and harmful functions
- CNS penetration: Ensuring adequate brain penetration
- Safety concerns: Immunosuppression risk
- sRAGE: Soluble RAGE in CSF and blood
- RAGE expression: Detected in neuroimaging
- Ligand levels: HMGB1, S100B in CSF
The study of Rage (Receptor For Advanced Glycation End Products) Signaling Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Bierhaus A, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2005
- Salloway S, et al. A phase 2 randomized trial of azeliragon in mild cognitive impairment due to Alzheimer's disease. Alzheimers Dement. 2019
- Ramasamy R, et al. Advanced glycation end products and RAGE in the pathogenesis of Alzheimer's disease. Exp Neurol. 2015
- Wang J, et al. RAGE and Alzheimer's disease: a progressive factor in the disease. J Alzheimers Dis. 2019
- Lue LF, et al. RAGE, aging and neurodegeneration. Aging Res Rev. 2010
- Zhang H, et al. RAGE in Parkinson's disease. Mov Disord. 2019
- Kim J, et al. HMGB1 and RAGE in ALS. Neurobiol Dis. 2018
- Srikanth V, et al. RAGE and peripheral neuropathy. Neurology. 2018
- Cai Z, et al. Role of RAGE in Alzheimer's disease. Cell Mol Neurobiol. 2016
- Grossi PM, et al. Targeting RAGE in neurodegeneration. Expert Opin Ther Targets. 2020
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 31%